ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901

In AbbVie’s pipeline, fr-alpha. Its studies are mostly in Ovarian Neoplasms, led by AbbVie.

Furthest: phase 1, since Dec 2, 20251 company-led study, 1 open or runningNext primary completion: Dec 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie11 open or runningphase 1since Dec 2, 2025Dec 2, 2025Dec 2028phase 1 · NCT07278336
  • Named in AbbVie’s own pipeline as ABBV-901, phase 1, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 2, 2025First study: phase 1 study in Ovarian NeoplasmsFirst studyNCT07278336 · 285 planned · United States, Australia, France and more

Ahead

  1. Dec 2028Primary completion: phase 1 study in Ovarian NeoplasmsNCT07278336

TargetBeta

“fr-alpha”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) ”NCIt, by rule

Other programs on FOLR1

ProgramCompanyFurthest phaseStudies
mirvetuximab soravtansineruleAbbViephase 315
rinatabart sesutecanruleGenmabphase 39
torvutatug samrotecanAstraZenecaphase 35
sofetabart mipitecanEli Lillyphase 32
opugotamig olatansineAbbViephase 22
Anti-FRa/Anti-CD3 Bispecific TCE NTB-928ruleteneoseven-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07278336Ovarian Neoplasms · United States, Australia, France and more1RecruitingDec 2028285

How it is read

Names in the registry

  • “ABBV-901”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.